menu
    • menu
    [{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Axsome Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jazz Pharmaceuticals \/ Axsome Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Jazz Pharmaceuticals \/ Axsome Therapeutics"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Sleep","graph2":"Phase IV","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"Dopamine reuptake","graph1":"Sleep","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Pharmanovia","pharmaFlowCategory":"D","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Sleep","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0.17000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Sleep","amount2New":0.17000000000000001,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Pharmanovia","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Pharmanovia"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Approved","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Psychiatry\/Psychology","graph2":"Phase III","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Axsome Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Axsome Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Solriamfetol Hydrochloride","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Axsome Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Axsome Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Axsome Therapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Solriamfetol Hydrochloride

    Menu

    Solriamfetol Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Highlights Data on Solriamfetol Showing Cognitive Improvement in Narcolepsy

                            Details : Sunosi (solriamfetol hcl) is a dopamine and norepinephrine reuptake inhibitor. It is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy.

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 29, 2024

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Initiates ENGAGE Phase 3 Trial of Solriamfetol for Binge Eating Disorder

                            Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of binge eating disorder.

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 01, 2024

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Initiates PARADIGM Phase 3 Of Solriamfetol For Major Depressive Disorder Treatment

                            Details : Sunosi (solriamfetol) is a dopamine and norepinephrine reuptake inhibitor and trace amine-associated receptor 1 (TAAR1) agonist. It is being evaluated for the treatment of major depressive disorder.

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 19, 2024

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Therapeutics Initiates FOCUS Phase 3 Trial of Solriamfetol for the Treatment of Attention Deficit Hyper...

                            Details : Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with Attention Deficit Hyperactivity Disorder (ADHD) in Adults.

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 07, 2023

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Psychiatry/Psychology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Pharmanovia

                            Deal Size : $167.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Dev...

                            Details : Under the agreement, Pharmanovia will be responsible for the development and marketing of Sunosi (solriamfetol), a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults with EDS due to narcolepsy or OSA, in Eur...

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : $66.0 million

                            February 22, 2023

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Pharmanovia

                            Deal Size : $167.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Therapeutics Announces Sunosi® (solriamfetol) Meets Primary Endpoint Demonstrating Improvement in Cogn...

                            Details : On the study’s primary endpoint, Sunosi (solriamfetol) demonstrated statistically significant improvement in cognitive function compared to placebo as assessed by the change from baseline on the DSST RBANS (6.49 vs. 4.75, p=0.009), with an effect size ...

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 03, 2022

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Therapeutics Announces Publication of Post-hoc Analysis of Sunosi® Effect on Excessive Daytime Sleepin...

                            Details : Sunosi (solriamfetol) is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI) indicated to improve wakefulness in adult patients with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 07, 2022

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Axsome Therapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Axsome Therapeutics Hosts Sunosi® Investor Update Virtual Event Today with Key Opinion Leaders

                            Details : Sunosi (solriamfetol) is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 28, 2022

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Jazz Pharmaceuticals

                            Ireland arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Jazz Pharmaceuticals

                            Ireland arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Axsome Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Jazz Pharmaceuticals Completes U.S. Divestiture of Sunosi® (solriamfetol) to Axsome Therapeutics

                            Details : Sunosi (solriamfetol), is a dual-acting dopamine and norepinephrine reuptake inhibitor shown to improve wakefulness in adults living with excessive daytime sleepiness (EDS) due to narcolepsy or obstructive sleep apnea (OSA).

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : $53.0 million

                            May 09, 2022

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Axsome Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Jazz Pharmaceuticals

                            Ireland arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Jazz Pharmaceuticals

                            Ireland arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Study Phase : Approved

                            Sponsor : Axsome Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neurosci...

                            Details : Axsome’s first-in-class DCC platform has been designed to optimize physician targeting and engagement, and promotional spend. The DCC platform and Axsome’s therapeutic focus will allow for increased reach to key Sunosi prescriber groups.

                            Brand Name : Sunosi

                            Molecule Type : Small molecule

                            Upfront Cash : $53.0 million

                            March 28, 2022

                            Lead Product(s) : Solriamfetol Hydrochloride

                            Therapeutic Area : Sleep

                            Highest Development Status : Approved

                            Sponsor : Axsome Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth